Towards novel translational safety biomarkers for adverse drug toxicity
Research Areas
At a Glance
- Status: Completed Consortium
- Year Launched: 2007
- Initiating Organization: TI Pharma
- Initiator Type: Nonprofit foundation
- No disease focus
- Location: International
Abstract
Mission
This project studies the metabolic effects of eight drugs (among which are paracetamol and diclofenac) with known side effects in the liver. By looking into the mechanics on a level ranging from the molecule to the patient, the researchers in this project aim to find biomarkers and develop tools for the early prediction of side effects of drugs. One of the breakthroughs in the project is the discovery that a person’s genetic profile appears to be one of the mechanics that have an influence on the resistance to adverse drug reactions. The ability to identify adverse effects in an early stage will prevent much discomfort in patients and economic loss.
Impact/Accomplishment
This project resulted in five Ph.D. theses:
Links/Social Media Feed
Homepage |
Sponsors & Partners
Abbott |
BioDetection Systems BV |
 BioFocus DPI |
Leiden University |
MSD |
NOTOX BV |
PamGene |
Pepscan Presto BV |
Radboud University Nijmegen Medical Centre |
University of Gronigen |
Utrecht University |
VU University Amsterdam |